Peak Bio, Inc. (PKBO) |
|
1.43 -0.22 (-13.33%)
|
01-27 15:52 |
|
Open: |
1.53 |
Pre. Close: |
1.65 |
|
High:
|
1.5741 |
Low:
|
1.43 |
|
Volume:
|
3,526 |
Market Cap:
|
29(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:07 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.7  One year: 6.89 |
| Support: |
Support1: 1 Support2: 0.84 |
| Resistance: |
Resistance1: 4.03 Resistance2: 5.9 |
| Pivot: |
1.81 |
| Moving Average: |
MA(5): 1.6 MA(20): 2.36
MA(100): 6.71 MA(250): 8.6 |
| MACD: |
MACD(12,26): -0.9  Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 14 %D(3): 15.3 |
| RSI: |
RSI(14): 26.1 |
| 52-week: |
High: 15 Low: 1 |
| Average Vol(K): |
3-Month: 404 (K) 10-Days: 8 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PKBO ] has closed above bottom band by 32.0%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.58 - 1.59 |
1.59 - 1.59 |
|
Low:
|
1.4 - 1.42 |
1.42 - 1.43 |
|
Close:
|
1.41 - 1.43 |
1.43 - 1.44 |
|
Company Description |
|
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California. |
Headline News |
Mon, 09 Jan 2023
Healthcare Stocks Moving Monday: CINC, APGN, AMYT, ALBO, PKBO, CERS, CUTR, ARWR - InvestorsObserver
Mon, 09 Jan 2023
U.S. shares mixed at close of trade; Dow Jones Industrial Average ... - Investing.com UK
Mon, 09 Jan 2023
U.S. stocks mixed at close of trade; Dow Jones Industrial Average ... - Investing.com
Mon, 28 Nov 2022
Healthcare Stocks Moving Monday: AXSM, NUTX, KTRA, IOBT, CINC, TCBP, PKBO, ONCS - InvestorsObserver
Fri, 04 Nov 2022
What Is Going on With Peak Bio (PKBO) Stock Today? - InvestorPlace
Thu, 03 Nov 2022
Peak Bio Stock (OTC:PKBO), Quotes and News Summary - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
3.2e+006 (%) |
|
% Held by Institutions
|
39.3 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-8.85e+006 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
839.2 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
489990 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
